Skip to content

The EXPLORE MG Registry for Myasthenia Gravis

Exploring Outcomes and Characteristics of Myasthenia Gravis: The EXPLORE MG Registry

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03792659
Enrollment
800
Registered
2019-01-03
Start date
2016-03-30
Completion date
2026-10-30
Last updated
2025-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myasthenia Gravis

Brief summary

The purpose of this study is to create a Yale University Department of Neurology Myasthenia Gravis (MG) registry that will be used for current and future research projects involving the study of Myasthenia Gravis.

Detailed description

This registry will allow for the research of several mechanisms of Myasthenia Gravis (MG) by studying peripheral blood, stool, disease status and course, and treatment of subjects with MG. The EXPLORE-MG Registry focuses on varied aspects of MG such as disease management, health care utilization, health costs, disease characteristics, and diagnostic tools. As such, it will aid in a broader understanding of MG, while providing a registry from which questions about the disease may be better answered.

Interventions

Approximately 100 cc (less than 1/2 cup) of blood will be drawn from both groups.

Sponsors

Yale University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patients diagnosed with Myasthenia Gravis presenting to the Yale Department of Neurology for clinical care or research interventions will be invited to donate their biological specimens/clinical data.

Exclusion criteria

* Failure to meet the Inclusion Criteria.

Design outcomes

Primary

MeasureTime frameDescription
The number of successful blood draws will be reported at the conclusion of the sample collection8 yearsSuccessful Collection of Blood

Secondary

MeasureTime frameDescription
The number of stool samples collected will be reported at the conclusion of the sample8 yearsCount of Stool Samples

Countries

United States

Contacts

Primary ContactBailey Sheldon, PhD
bailey.munrosheldon@yale.edu203-737-7095

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026